Dae Sik Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dae Sik Kim has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Chul Won Choi
Division of Hemato-oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
5 shared publications- Chul Won Choi
Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea
5 shared publications Eun Sang Yu
Division of Hemato-oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
5 shared publicationsMin Ji Jeon
Korea Univ, Guro Hosp, Sch Med, Div Hematol Oncol,Dept Internal Med, 148 Gurodong Ro, Seoul 08308, South Korea
4 shared publications- Min Ji Jeon
Division of Hemato-oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
4 shared publications Yong Park
Division of Hematology‐Oncology, Department of Internal Medicine Korea University Anam Hospital Seoul Korea
4 shared publications
Latest Publications
- Open Access
- 30 June 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (1) , 24-28
Erythrodermic psoriasis associated with Castleman disease: a case report
Ko Eun Kim, Han-Na Kim, Jiehyun Jeon, Dae Sik Kim, Yoo Sang Baek. Journal of the Korean Society for Psoriasis 2025;22:24-8. https://doi.org/10.23203/JKSP.2025.22.1.24
- 30 June 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (1) , 24-28
Open AccessErythrodermic psoriasis associated with Castleman disease: a case report
Ko Eun Kim, Han-Na Kim, Jiehyun Jeon, Dae Sik Kim, Yoo Sang Baek. Journal of the Korean Society for Psoriasis 2025;22:24-8. https://doi.org/10.23203/JKSP.2025.22.1.24
- Open Access
- 15 October 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (4) , 1262-1269
Long-term Psychiatric and Endocrine Complications Following Hematopoietic Stem Cell Transplantation in Hematologic Disease in Korea: A Nation-Wide Cohort Study
Purpose Numerous patients experience long-term complications after hematopoietic stem cell transplantation (HSCT). This study aimed to identify the frequency and risk factors for psychiatric and endocrine complications following HSCT through big data analyses.Materials and Methods We established a cohort of patients with hematologic disease who underwent HSCT in Korea between 2010 and 2012 using the Health Insurance Review & Assessment Service data. A total of 3,636 patients were identified, and insurance claims were tracked using psychiatric and endocrine diagnostic International Classification of Diseases, 10th Revision codes for the ensuing decade. We identified the incidence rates of long-term complications based on the baseline disease and HSCT type. Prognostic factors for each complication were scrutinized using logistic regression analysis.Results A total of 1,879 patients underwent allogeneic HSCT and 1,757 patients received autologous HSCT. Post-HSCT, 506 patients were diagnosed with depression, 465 with anxiety disorders, and 659 with diabetes. The highest incidence of long-term complications occurred within the first year post-HSCT (12.2%), subsequently decreasing over time. Risk factors for depressive disorders after allogeneic HSCT included female sex, a total body irradiation–based conditioning regimen, and cyclosporine. Identified risk factors for diabetes mellitus comprised old age, total body irradiation–based conditioning regimen, and non-antithymocyte globulin protocol. Regarding autologous HSCT, only female sex was identified as a risk factor for depressive disorders, whereas elderly patients and those with multiple myeloma were identified as poor prognostic factors for diabetes mellitus.Conclusion The incidence of long-term psychiatric and endocrine complications post-HSCT remains high, and patients with risk factors for these complications require vigilant follow-up.
- 15 October 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (4) , 1262-1269
Open AccessLong-term Psychiatric and Endocrine Complications Following Hematopoietic Stem Cell Transplantation in Hematologic Disease in Korea: A Nation-Wide Cohort Study
Purpose Numerous patients experience long-term complications after hematopoietic stem cell transplantation (HSCT). This study aimed to identify the frequency and risk factors for psychiatric and endocrine complications following HSCT through big data analyses.Materials and Methods We established a cohort of patients with hematologic disease who underwent HSCT in Korea between 2010 and 2012 using the Health Insurance Review & Assessment Service data. A total of 3,636 patients were identified, and insurance claims were tracked using psychiatric and endocrine diagnostic International Classification of Diseases, 10th Revision codes for the ensuing decade. We identified the incidence rates of long-term complications based on the baseline disease and HSCT type. Prognostic factors for each complication were scrutinized using logistic regression analysis.Results A total of 1,879 patients underwent allogeneic HSCT and 1,757 patients received autologous HSCT. Post-HSCT, 506 patients were diagnosed with depression, 465 with anxiety disorders, and 659 with diabetes. The highest incidence of long-term complications occurred within the first year post-HSCT (12.2%), subsequently decreasing over time. Risk factors for depressive disorders after allogeneic HSCT included female sex, a total body irradiation–based conditioning regimen, and cyclosporine. Identified risk factors for diabetes mellitus comprised old age, total body irradiation–based conditioning regimen, and non-antithymocyte globulin protocol. Regarding autologous HSCT, only female sex was identified as a risk factor for depressive disorders, whereas elderly patients and those with multiple myeloma were identified as poor prognostic factors for diabetes mellitus.Conclusion The incidence of long-term psychiatric and endocrine complications post-HSCT remains high, and patients with risk factors for these complications require vigilant follow-up.
- 5 August 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (5) , 1773-1781
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma
Summary: The optimal treatment strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) has yet to be established, especially in the elderly. In the current study, we conducted a phase II study to evaluate the efficacy and safety of rituximab plus high‐dose MTX followed by rituximab plus cytarabine in patients aged ≥60 years newly diagnosed with PCNSL. Patients received an induction treatment of high‐dose methotrexate plus rituximab followed by two cycles of a consolidation treatment of cytarabine plus rituximab. The primary end‐point was a 2‐year progression‐free survival (PFS) rate. A total of 35 patients were recruited, and their median age was 73 (range: 60–81). After induction treatment, the complete and partial responses (PRs) were 56% and 20% respectively. Twenty‐six patients proceeded to the consolidation treatment; the complete and PRs were 59% and 9% respectively. After a median follow‐up duration of 36.0 months, the 2‐year PFS rate was 58.7%. Treatment was generally well‐tolerated as only three patients were withdrawn from the study due to toxicity, and no treatment‐related mortality was reported. The 2‐year overall survival rate was 77.9%. The current study may suggest the feasibility of administering high‐dose MTX plus cytarabine in PCNSL patients aged ≥60 years and the potential role of additive rituximab.
- 5 August 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (5) , 1773-1781
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma
Summary: The optimal treatment strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) has yet to be established, especially in the elderly. In the current study, we conducted a phase II study to evaluate the efficacy and safety of rituximab plus high‐dose MTX followed by rituximab plus cytarabine in patients aged ≥60 years newly diagnosed with PCNSL. Patients received an induction treatment of high‐dose methotrexate plus rituximab followed by two cycles of a consolidation treatment of cytarabine plus rituximab. The primary end‐point was a 2‐year progression‐free survival (PFS) rate. A total of 35 patients were recruited, and their median age was 73 (range: 60–81). After induction treatment, the complete and partial responses (PRs) were 56% and 20% respectively. Twenty‐six patients proceeded to the consolidation treatment; the complete and PRs were 59% and 9% respectively. After a median follow‐up duration of 36.0 months, the 2‐year PFS rate was 58.7%. Treatment was generally well‐tolerated as only three patients were withdrawn from the study due to toxicity, and no treatment‐related mortality was reported. The 2‐year overall survival rate was 77.9%. The current study may suggest the feasibility of administering high‐dose MTX plus cytarabine in PCNSL patients aged ≥60 years and the potential role of additive rituximab.
- Open Access
- 1 November 2023
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 38 (6) , 893-902
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
Background/Aims: Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge.Methods: We developed a rituximab-resistant cell line (RRCL) by sequential exposure to gradually increasing concentrations of rituximab in a rituximab-sensitive cell line (RSCL). When the same dose of rituximab was administered, RRCL showed a smaller decrease in cell viability and apoptosis than RSCL. To determine the differences in gene expression between RSCL and RRCL, we performed next-generation sequencing.Results: In total, 1,879 differentially expressed genes were identified, and in the over-representation analysis of Consensus-PathDB, mitogen-activated protein kinase (MAPK) signaling pathway showed statistical significance. MAPK13, which encodes the p38δ protein, was expressed more than four-fold in RRCL. Western blot analysis revealed that phosphop38 expression mainwas increased in RRCL, and when p38 inhibitor was administered, phosphop38 expression was significantly decreased. Therefore, we hypothesized that p38 MAPK activation was associated with rituximab resistance. Previous studies have suggested that p38 is associated with NF-κB activation. Deferasirox has been reported to inhibit NF-κB activity and suppress phosphorylation of the MAPK pathway. Furthermore, it also has cytotoxic effects on various cancers and synergistic effects in overcoming drug resistance. In this study, we confirmed that deferasirox induced dose-dependent cytotoxicity in both RSCL and RRCL, and the combination of deferasirox and rituximab showed a synergistic effect in RRCL at all combination concentrations.Conclusions: We suggest that p38 MAPK, especially p38δ, activation is associated with rituximab resistance, and deferasirox may be a candidate to overcome rituximab resistance.
- 1 November 2023
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 38 (6) , 893-902
Open AccessIdentification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
Background/Aims: Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge.Methods: We developed a rituximab-resistant cell line (RRCL) by sequential exposure to gradually increasing concentrations of rituximab in a rituximab-sensitive cell line (RSCL). When the same dose of rituximab was administered, RRCL showed a smaller decrease in cell viability and apoptosis than RSCL. To determine the differences in gene expression between RSCL and RRCL, we performed next-generation sequencing.Results: In total, 1,879 differentially expressed genes were identified, and in the over-representation analysis of Consensus-PathDB, mitogen-activated protein kinase (MAPK) signaling pathway showed statistical significance. MAPK13, which encodes the p38δ protein, was expressed more than four-fold in RRCL. Western blot analysis revealed that phosphop38 expression mainwas increased in RRCL, and when p38 inhibitor was administered, phosphop38 expression was significantly decreased. Therefore, we hypothesized that p38 MAPK activation was associated with rituximab resistance. Previous studies have suggested that p38 is associated with NF-κB activation. Deferasirox has been reported to inhibit NF-κB activity and suppress phosphorylation of the MAPK pathway. Furthermore, it also has cytotoxic effects on various cancers and synergistic effects in overcoming drug resistance. In this study, we confirmed that deferasirox induced dose-dependent cytotoxicity in both RSCL and RRCL, and the combination of deferasirox and rituximab showed a synergistic effect in RRCL at all combination concentrations.Conclusions: We suggest that p38 MAPK, especially p38δ, activation is associated with rituximab resistance, and deferasirox may be a candidate to overcome rituximab resistance.
- 5 July 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (6) , E54-E57
Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma
- 5 July 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (6) , E54-E57
Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma
- Open Access
- 21 April 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (5) , 503-507
Implications of the 5th Edition of the World Health Organization Classification and International Consensus Classification of Myeloid Neoplasm in Myelodysplastic Syndrome With Excess Blasts and Acute Myeloid Leukemia
Cheonghwa Lee, M.D., Ha Nui Kim, M.D., Ph.D., Jung Ah Kwon, M.D., Ph.D., Soo-Young Yoon, M.D., Ph.D., Min Ji Jeon, M.D., Ph.D., Eun Sang Yu, M.D., Dae Sik Kim, M.D., Ph.D., Chul Won Choi, M.D., Ph.D., and Jung Yoon, M.D., Ph.D.. Ann Lab Med 2023;43:503-7. https://doi.org/10.3343/alm.2023.43.5.503
- 21 April 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (5) , 503-507
Open AccessImplications of the 5th Edition of the World Health Organization Classification and International Consensus Classification of Myeloid Neoplasm in Myelodysplastic Syndrome With Excess Blasts and Acute Myeloid Leukemia
Cheonghwa Lee, M.D., Ha Nui Kim, M.D., Ph.D., Jung Ah Kwon, M.D., Ph.D., Soo-Young Yoon, M.D., Ph.D., Min Ji Jeon, M.D., Ph.D., Eun Sang Yu, M.D., Dae Sik Kim, M.D., Ph.D., Chul Won Choi, M.D., Ph.D., and Jung Yoon, M.D., Ph.D.. Ann Lab Med 2023;43:503-7. https://doi.org/10.3343/alm.2023.43.5.503
- Open Access
- 30 April 2022
- Published by Springer Nature in Blood Research
- Vol. 57 (S1) , S112-S119
Recent advances in treatments of adult immune thrombocytopenia
Dae Sik Kim. Blood Res 2022;57:S112-9. https://doi.org/10.5045/br.2022.2022038
- 30 April 2022
- Published by Springer Nature in Blood Research
- Vol. 57 (S1) , S112-S119
Open AccessRecent advances in treatments of adult immune thrombocytopenia
Dae Sik Kim. Blood Res 2022;57:S112-9. https://doi.org/10.5045/br.2022.2022038
- Open Access
- 8 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (6) , 1477
Postoperative Thromboembolism According to the Type of Surgery: A Nationwide Study in the Republic of Korea
Postoperative thromboembolism (TE) is a serious, but preventable, complication in surgical patients. Orthopedic surgery, neurosurgery, and vascular surgery are considered high risk for TE, and current guidelines recommend TE prophylaxis. However, insufficient data exist regarding TE risk in other general surgeries. This study identified the actual incidence and relative risk of postoperative TE in the real world, according to surgery type. Twenty-six surgeries between 1 December 2017 and 31 August 2019 were selected from the Health Insurance Review and Assessment Service database and analyzed for postoperative TE events. Among all patients, 2.17% had a TE event within 6 months of surgery and 0.75% had a TE event owing to anticoagulant treatment. The incidence of total TE events was the highest in total knee replacement (12.77%), hip replacement (11.46%), and spine surgery (5.98%). The incidence of TE with anticoagulant treatment was the highest in total knee replacement (7.40%), hip replacement (7.20%), and coronary artery bypass graft (CABG) surgery (3.81%). Hip replacement, total knee replacement, CABG surgery, spine surgery, and cardiac surgery except CABG surgery, showed relatively higher risks for total claimed venous TE. The relative risk of venous TE with anticoagulant treatment was the highest for hysterectomy, partial hepatectomy, hip replacement, cardiac surgery except CABG surgery, and total knee replacement. The relative risk of arterial TE was the highest for cardiac surgery, total knee replacement, and hip replacement. In the real world, the incidence of postoperative TE events from total knee replacement and those from hip replacement remain high, and some surgeries could have a relatively higher risk of TE than other surgeries. For patients undergoing these surgeries, studies to reduce the incidence of postoperative TE in clinical practice should be conducted.
- 8 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (6) , 1477
Open AccessPostoperative Thromboembolism According to the Type of Surgery: A Nationwide Study in the Republic of Korea
Postoperative thromboembolism (TE) is a serious, but preventable, complication in surgical patients. Orthopedic surgery, neurosurgery, and vascular surgery are considered high risk for TE, and current guidelines recommend TE prophylaxis. However, insufficient data exist regarding TE risk in other general surgeries. This study identified the actual incidence and relative risk of postoperative TE in the real world, according to surgery type. Twenty-six surgeries between 1 December 2017 and 31 August 2019 were selected from the Health Insurance Review and Assessment Service database and analyzed for postoperative TE events. Among all patients, 2.17% had a TE event within 6 months of surgery and 0.75% had a TE event owing to anticoagulant treatment. The incidence of total TE events was the highest in total knee replacement (12.77%), hip replacement (11.46%), and spine surgery (5.98%). The incidence of TE with anticoagulant treatment was the highest in total knee replacement (7.40%), hip replacement (7.20%), and coronary artery bypass graft (CABG) surgery (3.81%). Hip replacement, total knee replacement, CABG surgery, spine surgery, and cardiac surgery except CABG surgery, showed relatively higher risks for total claimed venous TE. The relative risk of venous TE with anticoagulant treatment was the highest for hysterectomy, partial hepatectomy, hip replacement, cardiac surgery except CABG surgery, and total knee replacement. The relative risk of arterial TE was the highest for cardiac surgery, total knee replacement, and hip replacement. In the real world, the incidence of postoperative TE events from total knee replacement and those from hip replacement remain high, and some surgeries could have a relatively higher risk of TE than other surgeries. For patients undergoing these surgeries, studies to reduce the incidence of postoperative TE in clinical practice should be conducted.
- Open Access
- 15 January 2022
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 56 (1) , 57-60
Composite follicular lymphoma and classic Hodgkin lymphoma
Composite lymphoma is very rare and a combination of Hodgkin lymphoma and non-Hodgkin lymphoma and even histiocytic tumors can occur. Because of the unfamiliarity, not only can this cause diagnostic problems, but can also affect treatment plan. We report a case of composite lymphoma in a 40-year-old male. Initial biopsy showed a composite lymphoma of follicular lymphoma grade 1 and classic Hodgkin lymphoma. After chemotherapy, another lymph node was taken because of disease progression, which revealed follicular lymphoma, grade 3a without Hodgkin lymphoma component.
- 15 January 2022
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 56 (1) , 57-60
Open AccessComposite follicular lymphoma and classic Hodgkin lymphoma
Composite lymphoma is very rare and a combination of Hodgkin lymphoma and non-Hodgkin lymphoma and even histiocytic tumors can occur. Because of the unfamiliarity, not only can this cause diagnostic problems, but can also affect treatment plan. We report a case of composite lymphoma in a 40-year-old male. Initial biopsy showed a composite lymphoma of follicular lymphoma grade 1 and classic Hodgkin lymphoma. After chemotherapy, another lymph node was taken because of disease progression, which revealed follicular lymphoma, grade 3a without Hodgkin lymphoma component.
- 7 January 2022
- Published by Springer Nature in Virchows Archiv
- Vol. 481 (1) , 125-129
Peripheral T cell lymphoma of the nasopharynx with expansion of EBV-positive B cells masquerading as an extranodal NK/T cell lymphoma, nasal type
Epstein-Barr virus-infected B cells are found at high frequency in peripheral T cell lymphoma. Herein, we report a case involving excessive EBV-positive B cells accompanying peripheral T cell lymphoma, not otherwise specified in the nasopharynx masquerading as nasopharyngeal extranodal NK/T cell lymphoma. A large number of Epstein-Barr virus-infected B cells infiltrate in between CD3-positive cytotoxic tumor T cells, as if EBV was infecting tumor T cells. After chemotherapy, the T cell lymphoma population decreased, but the B cell population expanded to form EBV-positive diffuse large B cell lymphoma in the tonsils and nasopharynx. At the follow-up, bone marrow biopsy exhibited infiltration of composite peripheral T cell lymphoma, not otherwise specified, and EBV-positive diffuse large B cell lymphoma. Although this condition is rare, the cell lineage of EBV-infected cells must be confirmed when diagnosing extranodal NK/T cell lymphoma to exclude the possibility of misdiagnosis by Epstein-Barr virus-infected B cells.
- 7 January 2022
- Published by Springer Nature in Virchows Archiv
- Vol. 481 (1) , 125-129
Peripheral T cell lymphoma of the nasopharynx with expansion of EBV-positive B cells masquerading as an extranodal NK/T cell lymphoma, nasal type
Epstein-Barr virus-infected B cells are found at high frequency in peripheral T cell lymphoma. Herein, we report a case involving excessive EBV-positive B cells accompanying peripheral T cell lymphoma, not otherwise specified in the nasopharynx masquerading as nasopharyngeal extranodal NK/T cell lymphoma. A large number of Epstein-Barr virus-infected B cells infiltrate in between CD3-positive cytotoxic tumor T cells, as if EBV was infecting tumor T cells. After chemotherapy, the T cell lymphoma population decreased, but the B cell population expanded to form EBV-positive diffuse large B cell lymphoma in the tonsils and nasopharynx. At the follow-up, bone marrow biopsy exhibited infiltration of composite peripheral T cell lymphoma, not otherwise specified, and EBV-positive diffuse large B cell lymphoma. Although this condition is rare, the cell lineage of EBV-infected cells must be confirmed when diagnosing extranodal NK/T cell lymphoma to exclude the possibility of misdiagnosis by Epstein-Barr virus-infected B cells.